10/530986

JC13 Rec'd PCT/PTO 12 APR 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

		•
In re application of:	Burgess, et al.	
International App. No.:	PCT/US2003/032625	Group Art Unit:
International Filing Date:	October 15, 2003	Examiner:
For:	CHEMICAL COMPOUNDS	
Commissioner for Patent Washington, D.C. 20231		
	INFORMATION DISCLO	SURE STATEMENT
Applicants request th Examiner and officially m	nat the references identified on Form ade of record in accordance with the	PTO-1449 appended hereto be considered by the provisions of 37 CFR 1.97
[X] A copy of the Interpersion PCT/US2003/03: Report are listed to the U.S. Patent A. [X] The Information of Filing day applicate occurs in OR	erences were submitted in parent appernational Search Report which issue 2625 is submitted herewith. All of the on the attached form PTO-1449 and the Office by the International Bureau. The ormation Disclosure Statement submate of the above application or date of ion or before the mailing date of a finast. 37 CFR 1.97(b).	he publications cited in the International Search I Applicants understand that copies have been supplied whitted herewith is being filed within three months of the of entry into the national stage of an international arst Office action on the merits, whichever event
of a firs	ormation Disclosure Statement su st office action after the filing of a 1.114 (37 C.F.R. 1.97(b)(4)).	bmitted herewith is being filed before the mailing Request For Continued Examination under 37
filing date of an internatio event occurre (1) a fir (2) a no whichever occurs	f the above application or the date of mal application or after the mailing of ed last, but before the mailing date of all action under § 1.113 or otice of allowance under § 1.311, as first.	
		mation contained in this Information Disclosure

application not more than three months prior to the filing of this statement.

Disclosure Statement under § 1.97(c) (\$240.00).

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information

10/530 986 JC13 Rec'd PCT/PTO 12 APR 2005

C. [[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under §
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

John L. Lemanowicz Attorney for Appliant

Registration No. 37,380

Date:

GlaxoSmithKine

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8247 Facsimile: (919) 483-7988

10/530986

JC13 Rec'd PCT/PTO 12 APR 2005 ATTORNEY DOCKET INTERNATIONAL **FORM PTO-1449** NO. APP. NO. INFORMATION DISCLOSURE STATEMENT PCT/US2003/032625 PU4969USW APPLICANT Burgess et al. **INTERNATIONAL GROUP FILING DATE** 10/15/03 **U.S. PATENT DOCUMENTS** Filing Date Examiner **Subclass Patent Issue Date** Name Class Appropriate **Initials** Number 5,441,949 8/15/95 Jung et al. 1 Continue on page FOREIGN PATENT DOCUMENTS Translation Document Publication Date Class **Subclass** Number Country Continue on page OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Continue on page DATE CONSIDERED **EXAMINER**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.